Affinity Chromatography (AC)

Total Page:16

File Type:pdf, Size:1020Kb

Affinity Chromatography (AC) Affinity Chromatography (AC) 1 Affinity Chromatography (AC) • Principles of AC • Main stages in Chromatography • How to prepare Affinity gel - Ligand Immobilization - Spacer arms – Coupling methods – Coupling tips • Types of AC • Elution Conditions • Binding equilibrium, competitive elution, kinetics • Industrial Examples: Protein A/G for Therapeutic proteins • Future Considerations 2 What is affinity chromatography? Affinity chromatography is a technique of liquid chromatography which separates molecules through biospecific interactions. The molecule to be purified is specifically and reversibly adsorbed to a specific ligand The ligand is immobilized to an insoluble support (“matrix”): resin, “chip”, Elisa plate, membrane, Western, IP (immuneprecipitation), etc Introduction of a “spacer arm” between the ligand and the matrix to improve binding Elution of the bound target molecule a) non specific or b) specific elution method 3 What is it used for? Monoclonal and polyclonal antibodies Fusion proteins Enzymes DNA-binding proteins . ANY protein where we have a binding partner!! 4 Designing and preparing an affinity gel Choosing the matrix Designing the ligand - Spacer arms Coupling methods 5 Ligand Immobilization Ligand + Activating agent + Matrix Activated Immobilised matrix ligand 6 Designing the ligand Essential ligand properties: interacts selectively and reversibly with the target Carries groups which can couple it to the matrix without losing its binding activity Available in a pure form 7 Steric considerations & spacer arms Small ligand (<1,000) Risk of steric interference with binding between matrix and target molecule Often need spacer arm but watch out for Spacer arm adsorption to the spacer! 8 Design of spacer arms Alkyl chain Real risk of unspecific interactions between H H spacer and target molecule O O Hydrophilic chain Risk of unspecific interactions greatly O H reduced No coupling reaction will use 100% of the available binding sites. Using a gel with pre-attached spacer arms will leave some uncoupled spacers, increasing the possibility of non-specific interactions. The unused spacer arms should not be too much of a problem if they are hydrophilic. If available, this problem may be eliminated by using a ligand with a pre-attached spacer arm. 9 Choosing a coupling group • Ligands are coupled to the matrix via reactive groups Amino -NH2 Hydroxyl -OH Aldehyde -CHO Thiol -SH Carboxyl -COOH • Coupling must allow a free binding site 10 Useful Coupling Methods Coupling chemistry Kinds of group coupled Ligand N-hydroxysuccinimide -NH2 Protein ,Peptide. Sugar.Polynucleotide.Cofactor CNBr -NH2 Protein , Sugar.Polynucleotide.Cofactor Carbodiimide -NH2 Small ligands. Non polar ligand in organic via hydrophilic spacer arm solvents. Derivatized material Epoxide -SH-NH2-OH Sugars. Small ligands via hydrophilic spacer arm Thiol exchange -SH Protein ,Peptide. Polynucleotide Mild Conditions Low MW thiol containig ligand 11 Useful Coupling Methods Cyanogen bromide activation O C N O + Gel C N + H Br Gel H Br Sepharose Cyanogen Cyanate ester bromide formed Cyanogen bromide coupling H O Lig NH O N Gel C N + 2 Gel C Lig CNBr-activated NH Protein ligand N-substituted isourea Sepharose Reaction at pH 8. Isourea may be cleaved by nucleophilic attack at high pH. Multiple bonds formed with protein ligands. No spacer arm present. 12 WARNING!: Cyanogen bromide is dangerous. Consult safety data before start working A general protocol for ligand coupling Prepare the ligand solution in coupling buffer Prepare the activated matrix Mix the ligand solution and the activated gel in coupling buffer until coupling is complete Check total ligand before and after coupling: ligand/ml resin Block any remaining active groups Wash the coupled gel alternately at high and low pH to remove adsorbed ligand Transfer to storage buffer 13 Tips: Preparing the activated matrix - couple buffer If the activated matrix is freeze-dried, allow it to swell before washing Always use the recommended swelling and washing solutions! The swelling, washing and equilibration are best performed on a sintered glass filter. Facilitates quickly removal of excess liquid from the media Couple buffer: make sure there are no components, e.g. amines, that can couple in place of the ligand, e.g. Tris buffer has a primary amine To suppress ionic adsorption, add NaCl, 0.5 M. pH is important. Always use the recommended pH. 14 Tips: Coupling reaction, washing and storage Ligands which are poorly soluble in water, may usually be added in an organic solvent. The ligand should be available at a high level of purity. Any contaminants present in the ligand sample will likely be coupled to the matrix. Mix the activated gel and the ligand solution by swirling or end-over-end mixing - Avoid magnetic stirrers as these can crush the gel and produce fines!! Take samples of ligand before and after reaction: to calculate ligand per ml resin Time and temperature according to standard protocols. Most coupling reactions are performed at room temperature Block any remaining active groups with a small neutral ligand (Tris buffer for amino reactions) Wash the coupled gel at alternating high and low pH to remove adsorbed substances. 15 Keep in storage buffer (Na Azide , Thimerosol 0.02% or ethanol if possible) G Protein Receptor Kinase Technique Pig brain homogenate Purification Comment factor Ppt Ammonium sulfate 7 precipitation A. Tobin et al. (1996) J. Biol. Chem. 271, 3907-3916 HIC Butyl Sepharose Fast 20 Flow AIEX RESOURCE Q CIEX RESOURCE S 2408 AC HiTrap Heparin 18647 • 10 mg homogenous protein 16 Membrane Protein Technique Placental extract in Purification Comment 1.5% Triton X-100 factor AC Blue Sepharose 3 • Concentration and capture AIEX DEAE Sephacel 4 T. White et al. (1995) J. Biol. Chem. 270, 24156-24165 CIEX SP Sepharose 6 AC Muc2 Sepharose 242 • Main purification step • Final polishing and purity CIEX Mono S 1442 check, 20 mg obtained 17 DNA-binding Protein Technique HeLa cell nuclear Purification Comment extract factor J. Berthelsen et al. (1996) J. Biol. Chem. 271, 3822-3830 CIEX SP Sepharose High 5 Performance AC Heparin Sepharose 8 • General AC step for DNA- Fast Flow binding proteins AC DNA-1 Sepharose 9 • Removal step, non-specific DNA binding activity removed AC DNA-2 Sepharose 2447 • Main purification step CIEX Mono S 4943 • Final polishing, 20 mg obtained 18 Advantages and Disadvantages of affinity chromatography • Easy to achieve otherwise difficult • Buffer / elution limitations: Sometimes needs harsh or denaturizing separations elution conditions Very expensive elution conditions • Often high purity in one step (but not always) • Economics (scale-up): Ligand stability affects life-time of • Relatively fast separations affinity resins (according to kinetics of binding and elution) Some ligands are very expensive • Can be use to remove specific • Do not resolve all the problems contaminants 19 The main stages in affinity chromatography Sample application Elution of the target Equilibration Wash Re-equilibration Of gel and sample contaminants Of the gel to binding conditions to binding conditions Or keep in storage buffer (20% Ethanol or 0.02%NaAzide in Buffer) 20 Columns and equipment Tips Column volume: according to amount of target and gel capacity Avoid using excess of resin: to avoid low affinity binding of impurities. Use maximum capacity of the column. Column length: not usually critical, short and wide Equipment: no special demands Equilibrate column before applying sample and follow standard protocol 21 Sample preparation Tips Adjust pH, buffer salts and additives to promote binding Filter or centrifuge to remove particles Make sure that components known to interfere with binding are absent Consider alternative capture step before affinity purification Eliminates crude impurities or interfering substances IEX or HIC columns are cheaper, with higher dynamic capacity and quickly concentrate lysates Prolongs resin half life (reduce cost) 22 Sample application Tips Binding buffer: usually neutral pH, and high salt concentration when is possible (0.3-0.5M NaCl) to avoid hydrophobic interactions of non specific proteins to the resin. Use additives only if necessary. Loading directly on column - Strong affinity and fast binding: High flow rate - Weak affinity and/or slow binding: Low flow rate 23 Kinetics of adsorption and desorption Unexpected results Slow binding Some targets do not completely bind to the resin: very low dynamic binding capacity Open columns: slow down binding. Stopped flow binding to bind the target in portions or rebind several times For batch binding, incubation of around 1.5 hours at 4°C is enough. For extremely slow binding kinetics, incubate overnight at 4°C. Very gentle stirring Binding on FPLC column: adjust flow rate to get loading in ~90min Slow desorption If target elutes as a long, low 'peak‘, reduce elution flow-rate Open columns: Stopped flow elution to elute the target in pulses. Change elution scheme Elution of FPLC column: extremely slow elution in order to get narrow peaks 24 Washing, elution and re equilibration Tips • Follow standard protocol • Optimize alternative wash strategies to increase final purity (high salt, detergents, others) • If eluting at extreme pH: collect the target protein in a small amount of concentrated buffer at a neutralizing pH • Re-equilibrate column immediately with binding or storage buffer • Regeneration: use buffers that do not harm the ligand 25 Column Regeneration Tips Wash with basic and acidic buffers. – 10 col. vol. 0.1 M Tris.HCl, 0.5 M NaCl, pH 8.5 – 10 col. vol. 0.1 M NaAc, 0.5 M NaCl, pH 4.5 – Use chaotropic agents or detergents if needed Re-equilibrate with 10 column volumes starting buffer. Use more if needed Ni columns can be washed with 0.5N NaOH, neutralized, destriped with 100mM neutral EDTA, wash, charge with 100mM Ni SO4, wash and store with 20% Ethanol 26 Column Storage Tips To maximize the useful lifetime of an affinity resin, choose a storage buffer that does not harm the ligand Typical buffers are 20% ethanol solution or binding buffer containing a bacteriostatic agent (e.g.
Recommended publications
  • Fig. 1C Combination Therapy of Tumor Targeted ICOS Agonists with T-Cell Bispecific Molecules
    ( (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/30 (2006.01) A61P 35/00 (2006.01) kind of national protection av ailable) . AE, AG, AL, AM, C07K 16/28 (2006.01) A 6IK 39/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C07K 16/40 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/EP20 18/086046 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 20 December 2018 (20. 12.2018) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available) . ARIPO (BW, GH, 17209444.3 2 1 December 2017 (21. 12.2017) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant (for all designated States except US): F. HOFF- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 124, 4070 Basel (CH).
    [Show full text]
  • International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU
    ( 2 (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 39/42 (2006.01) C07K 16/10 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, C07K 16/08 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 19/033 995 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 24 May 2019 (24.05.2019) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available) . ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/676,045 24 May 2018 (24.05.2018) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: LANKENAU INSTITUTE FOR MEDICAL TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, RESEARCH [US/US]; 100 Lancaster Avenue, Wyn- KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies
    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
    [Show full text]
  • Generation of Novel Intracellular Binding Reagents Based on the Human Γb-Crystallin Scaffold
    Generation of novel intracellular binding reagents based on the human γB-crystallin scaffold Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I-Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg Institut für Biochemie und Biotechnologie von Ewa Mirecka geboren am 17. Dezember 1976 in Gdynia, Polen Table of contents Table of contents 1. INTRODUCTION.........................................................................................................1 1.1 Monoclonal antibodies as a biomolecular scaffold..........................................................1 1.2 Binding molecules derived from non-immunoglobulin scaffolds.....................................3 1.2.1 Alternative protein scaffolds – general considerations............................................................ 3 1.2.2 Application of alternative binding molecules ........................................................................... 6 1.3 Affilin – novel binding molecules based on the human γB-crystallin scaffold................... 6 1.3.1 Human γB-crystallin as a molecular scaffold........................................................................... 6 1.3.2 Generation of a human γB-crystallin library and selection of first-generation Affilin molecules ................................................................................................................................ 8 1.4 Selection of binding proteins by phage display ...................................................................
    [Show full text]
  • Selection of an Artificial Binding Protein Against the Ectodomain of PTH1R
    Selection of an artificial binding protein against the ectodomain of PTH1R Dissertation Zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt bei der Naturwissenschaftlichen Fakultät I Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg von Qi Zhang geboren am 21.09.1983 in Shaanxi, China Gutachter /in 1. PD. Dr. Hauke Lilie 2. Prof. Dr. Jochen Balbach 3. Prof. Dr. Annette G. Beck-Sickinger Verteidigungsdatum: 14.03.2013 Zusammenfassung In den vergangenen Jahrzehnten fanden mehr als 30 Immunglobuline (IgGs) und deren Derivate Anwendung in der klinischen Praxis. Trotz des großen Erfolgs solcher Antikörper-basierter Medikamente traten auch einige Limitationen auf. Gerüstproteine stellen eine Alternative zu herkömmlichen Antikörpern dar. Sie weisen meist eine hohe thermodynamische Stabilität auf und bestehen aus einer einzelnen Polypeptidkette ohne Disulfidbrücken. Universelle Bindestellen können wie beim humanen Fibronectin III und bei Anticalinen in flexiblen Loop-Regionen erzeugt werden oder auf rigiden Sekundärstrukturelementen, wie im Fall der Affibodies, DARPine und Affiline. In der vorliegenden Arbeit wurde eine Protein-Bibliothek auf Basis des humanen γB-Kristallins, unter Randomisierung von 8 oberflächenexponierten Aminosäuren auf einem β-Faltblatt der N-terminalen Domäne des Proteins, hergestellt. Ein kürzlich entwickeltes Screening-System, das T7-basierte Phagen-Display, wurde zur Durchmusterung der Bibliothek auf potentielle Binder angewandt. Dabei erfolgt die Assemblierung der Protein-präsentierenden Phagenpartikel ohne einen Transportschritt über die Zellmembran hinweg bereits im Cytoplasma von E. coli. G-Protein gekoppelte Rezeptoren (GPCRs) bilden nur schwerlich für Strukturuntersuchungen geeignete, geordnete Kristallstrukturen aus. Kleine, gut lösliche Bindeproteine könnten sie in einer bestimmten Konformation fixieren und so den Anteil an hydrophilen Resten auf der Proteinoberfläche erhöhen.
    [Show full text]
  • Understanding Ubiquitin Recognition and Generating Affinity Reagents
    Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents by Isabel Leung A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Molecular Genetics University of Toronto © Copyright by Isabel Leung 2017 Abstract Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents Isabel Leung Doctor of Philosophy Department of Molecular Genetics University of Toronto 2016 Protein-protein interactions are necessary for virtually all biological processes. There have been tremendous efforts to document the diversity of molecular recognition, and to understand how molecular recognition occurs. The understanding of molecular interaction has also served as the foundation for designing novel protein interactions for use in therapeutics, diagnostics and basic sciences. An attractive system for studying protein-protein interactions is the ubiquitin (Ub) system. Ub is a protein modifier that is combinatorially ligated onto substrate proteins to influence substrate turnover and function. Ub uses a common surface to interact with more than 1000 proteins and plays pivotal roles in cell physiology. Despite the substantial structural information on Ub mediated interactions, there is no clear understanding of how individual Ub residues contribute to Ub’s broad scope of interactions. To address this question, I used affinity enhanced Ub variants (Ubvs) as proxies of native Ub in saturation scanning. Using saturation scanning, I studied the interactions between Ubvs and two Ub specific proteases (USP), USP2 and USP21, and elucidated a common functional epitope that is critical for USP recognition. The functional epitope recognizes USP residues that are conserved among the human USP family, suggesting it may make functional contributions in many other USP interactions.
    [Show full text]
  • WO 2018/218207 Al 29 November 2018 (29.11.2018) W !P O PCT
    (t) include a VL chain of SEQ ID NO: 24 and a VH chain of SEQ ID NO: 25; (u) include a VL chain of SEQ ID NO: 84 and a VH chain of SEQ ID NO: 83; (v) include a VL chain of SEQ ID NO: 154 and a VH chain of SEQ ID NO: 155; (w) include CDRs including SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; and SEQ ID NO: 90; (x) include CDRs including SEQ ID NO: 130; SEQ ID NO: 13 1; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; and SEQ ID NO: 135; (y) include CDRs including SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110 , and SEQ ID NO: 111; (z) include CDRs including SEQ ID NO: 112 , SEQ ID NO: 113 , SEQ ID NO: 114 , SEQ ID NO: 115 , SEQ ID NO: 116 , and SEQ ID NO: 117 ; (aa) include CDRs including SEQ ID NO: 118 , SEQ ID NO: 119 , SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, and SEQ ID NO: 123; (bb) include CDRs including SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, and SEQ ID NO: 129; (cc) include CDRs including SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, and SEQ ID NO: 14 1; (dd) include CDRs including SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, and SEQ ID NO: 147 (ee) include CDRs including SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, and SEQ ID NO: 99; (ff) include CDRs including SEQ ID NO: 100, SEQ ID NO: 10 1, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, and SEQ ID NO: 105; (gg) include CDRs including SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 15 1, SEQ ID NO: 152, and SEQ ID NO: 153; (hh) includes a humanized sequence of an antibody disclosed herein; and/or (ii) binds to endogenous human CD33 with a KD of less than 10 nM.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0112915 A1 Bardroff Et Al
    US 201401 12915A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0112915 A1 Bardroff et al. (43) Pub. Date: Apr. 24, 2014 (54) IL-18 BINDING MOLECULES Publication Classification (71) Applicants: Michael Otto Bardroff, Loerrach (DE); (51) Int. Cl. Barbara Brannetti, Basel (CH); Emma C07K 6/24 (2006.01) Michelle Campbell, Surrey (GB); Beate GOIN33/68 (2006.01) Diefenbach-Streiber, Windach (DE): (52) U.S. Cl. Adina Eberth, Munich (DE); Christian CPC .......... C07K 16/244 (2013.01); G0IN33/6854 Carsten Silvester Kunz, Muenchen (2013.01) (DE); Sylwia Marshall, Epsom (GB); USPC ... 424/133.1; 424/139.1; 435/7.92; 435/69.6; Jean-Michel Rene Rondeau, Rixheim 435/331; 435/320.1; 530/387.3; 530/387.9; (FR); Jean-Marc Alfred Schlaeppi, 536/2353 Allschwil (CH); Gino Anselmus Van Heeke, Upper Beeding (GB) (57) ABSTRACT (72) Inventors: Michael Otto Bardroff, Loerrach (DE); Barbara Brannetti, Basel (CH); Emma Michelle Campbell, Surrey (GB); Beate IL-18 participates in both innate and acquired immunity. The Diefenbach-Streiber, Windach (DE): bioactivity of IL-18 is negatively regulated by the IL-18 bind Adina Eberth, Munich (DE); Christian ing protein (IL18BP), a naturally occurring and highly spe Carsten Silvester Kunz, Muenchen cific inhibitor. This soluble proteinforms a complex with free (DE); Sylwia Marshall, Epsom (GB); IL-18 preventing its interaction with the IL-18 receptor, thus Jean-Michel Rene Rondeau, Rixheim neutralizing and inhibiting its biological activity. The present (FR); Jean-Marc Alfred Schlaeppi, invention discloses binding molecules, in particular antibod Allschwil (CH); Gino Anselmus Van ies or fragments thereof, which bind IL-18 and do not bind Heeke, Upper Beeding (GB) IL-18 bound to IL-18BP (IL-18/IL-18BP complex).
    [Show full text]
  • Download Book
    Methods in Molecular Biology 1701 Michael Hust Theam Soon Lim Editors Phage Display Methods and Protocols M ETHODS IN M OLECULAR B IOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Phage Display Methods and Protocols Edited by Michael Hust Technische Universit€at Braunschweig, Braunschweig, Germany Theam Soon Lim Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden, Penang, Malaysia Editors Michael Hust Theam Soon Lim Technische Universit€at Braunschweig Institute for Research in Molecular Medicine Braunschweig, Germany Universiti Sains Malaysia Minden, Penang, Malaysia ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-7446-7 ISBN 978-1-4939-7447-4 (eBook) DOI 10.1007/978-1-4939-7447-4 Library of Congress Control Number: 2017956713 © Springer Science+Business Media LLC 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication.
    [Show full text]
  • Suderman Et Al. 2017
    Protein Expression and Purification 134 (2017) 114e124 Contents lists available at ScienceDirect Protein Expression and Purification journal homepage: www.elsevier.com/locate/yprep Development of polyol-responsive antibody mimetics for single-step protein purification * Richard J. Suderman a, , Daren A. Rice a, Shane D. Gibson a, Eric J. Strick a, David M. Chao a, b a Nectagen, Inc., 2002 W. 39th Ave, Kansas City, KS 66103, USA b Stowers Institute for Medical Research, BioMed Valley Discoveries, Inc., USA article info abstract Article history: The purification of functional proteins is a critical pre-requisite for many experimental assays. Immu- Received 24 March 2017 noaffinity chromatography, one of the fastest and most efficient purification procedures available, is often Received in revised form limited by elution conditions that disrupt structure and destroy enzymatic activity. To address this 13 April 2017 limitation, we developed polyol-responsive antibody mimetics, termed nanoCLAMPs, based on a 16 kDa Accepted 15 April 2017 carbohydrate binding module domain from Clostridium perfringens hyaluronidase. nanoCLAMPs bind Available online 17 April 2017 targets with nanomolar affinity and high selectivity yet release their targets when exposed to a neutral polyol-containing buffer, a composition others have shown to preserve quaternary structure and enzy- Keywords: Affinity purification matic activity. We screened a phage display library for nanoCLAMPs recognizing several target proteins, fi fi Antibody mimetics produced af nity resins with the resulting nanoCLAMPs, and successfully puri ed functional target nanoCLAMPs proteins by single-step affinity chromatography and polyol elution. To our knowledge, nanoCLAMPs Immunoaffinity constitute the first antibody mimetics demonstrated to be polyol-responsive.
    [Show full text]
  • Beyond Antibodies Protein Engineering & Design
    Register Today to Hear New Data on Over 40 Antibody Alternative and Protein Engineering Projects IBC's 4th Annual Protein Beyond Engineering Antibodies & Design Novel Scaffolds, Clinical Progress Enabling Technologies and Creative and Manufacturing the Engineering to Improve Drug-Like Next Generation of Therapeutics Properties of Proteins September 21-23, 2009 • Town and Country Hotel • San Diego, CA Accelerate your own projects by applying Improve the functionality and biophysical lessons you will learn from multiple scaffolds properties of your molecules by applying progressing to the clinic: novel approaches to engineering: • Clinical and preclinical results of non-antibody • Engineering proteins for mulitfunctionality and antibody-like scaffolds • Improving half-life/PK, protein stability and delivery • FDA perspective on regulation of next generation antibodies and antibody alternatives • “Designer” protein engineering and computational modeling • Modified antibody formats: Bi-specifics and multi-specifics • Engineering and designing peptides, chemokines, enzymes and other scaffolds • Novel and emerging scaffolds • Conjugation approaches and new frontiers in • Downstream considerations to inform your protein engineering discovery and design efforts Keynote Presentation Featured Presentations Recombinant Immunotoxins: An FDA Perspective Building on Success in Hairy Cell Leukemia Marjorie Shapiro, Ph.D., CDER/FDA Ira Pastan, M.D., Chief, Laboratory of Molecular Biology, National Cancer Institute, NIH Two-in-One Antibody Germaine Fuh, Ph.D., Genentech Silver Scientific The Antibody Society Event Sponsor: Sponsor: Partner Register Early & Save www.IBCLifeSciences.com/Beyond Engineering the Next Generation of Protein Therapeutics This one-of-a-kind meeting features over 40 exclusive case studies giving you insights into novel strategies for accelerating antibody- like and non-antibody scaffolds to the clinic and emerging protein engineering and design strategies to improve properties of current platforms.
    [Show full text]
  • Camelid Single-Domain Antibody Directed Against Amyloid Bêta and Methods for Producing Conjugates Thereof
    (19) TZZ ¥_T (11) EP 2 873 679 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.05.2015 Bulletin 2015/21 C07K 16/18 (2006.01) A61K 49/16 (2006.01) A61K 51/10 (2006.01) (21) Application number: 13306553.2 (22) Date of filing: 13.11.2013 (84) Designated Contracting States: • Delatour, Benoît AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 94230 Cachan (FR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Dhenain, Marc PL PT RO RS SE SI SK SM TR 91470 Limours (FR) Designated Extension States: • Duyckaerts, Charles BA ME 94160 Saint-Mandé (FR) • Li, Tengfei (83) Declaration under Rule 32(1) EPC (expert 92400 Courbevoie (FR) solution) • Vandesquille, Matthias 92260 Fontenay-aux-Roses (FR) (71) Applicants: • Czech, Christian • F.Hoffmann-La Roche AG 79639 Grenzach-Wyhlen (DE) 4070 Basel (CH) • Grueninger, Fiona • INSTITUT PASTEUR 4144 Arlesheim (CH) 75015 Paris (FR) (74) Representative: Rançon, Xavier Lucien Abel et al (72) Inventors: Cabinet Orès • Lafaye, Pierre 36, rue de Saint Pétersbourg 92240 Malakoff (FR) 75008 Paris (FR) • Bay, Sylvie 75012 Paris (FR) (54) Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof (57) The present invention relates to variable domain of a camelid heavy- chain antibodies directed to amyloid β and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid β deposits. EP 2 873 679 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 873 679 A1 Description [0001] The present invention relates to antibodies directed to amyloid β and conjugates thereof.
    [Show full text]